Effect and Safety Study of GP/FP Regimens in Advanced Nasopharyngeal Carcinoma
Status:
Completed
Trial end date:
2020-12-20
Target enrollment:
Participant gender:
Summary
The present study will be a randomized, control, multicenter phase III study of recurrent or
metastatic (R/M) nasopharyngeal carcinoma (NPC) treated with Gemcitabine (Gemzar, Lilly) and
cisplatin regimen (GP) or 5-Fluorouracil plus cisplatin regimen (FP). The population consists
of recurrent or metastatic nasopharyngeal carcinoma (NPC) that failed the radical
radiotherapy or chemotherapy-naïve advanced NPC (stage IV). The effectiveness and side
effects will be evaluated according to Standard WHO response criteria and NCI-CTC AE V3.0.